First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study

Autor: Karim Amrane, Gilles Robinet, Ronan Abgral, Gilles Quere, Jean-Louis Bizec, Éric Goarant, Sylvie Gouva, Cyril Bernier, Renaud Descourt, R. Lamy, Hervé Lena, Guillaume Léveiller, Florence Gadby, Ulrike Schick, Margaux Geier, Romain Corre, Christos Chouaid
Přispěvatelé: CHRU Brest, F-29200 Brest, France, Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Hôpital Morvan - CHRU de Brest (CHU - BREST ), Centre Hospitalier Intercommunal de Cornouaille [Quimper] (CHI Cornouaille [Quimper]), Chemistry, Oncogenesis, Stress and Signaling (COSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Yves le Foll, CH des Pays Morlaix, CH Bretagne Sud, CH Bretagne Atlantique, CH de Saint-Malo, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), CHRU Brest - Service de médecine nucléaire (CHU - BREST - Med Nucléaire), Laboratoire de Traitement de l'Information Medicale (LaTIM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-IMT Atlantique (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Centre hospitalier Rene Pleven de Dinan, Biomécanique cellulaire et respiratoire (BCR), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Centre National de la Recherche Scientifique (CNRS), Service de Pneumologie [CHI Créteil], CHI Créteil, IMRB - CEPIA/'Clinical Epidemiology And Ageing : Geriatrics, Primary Care and Public Health' [Créteil] (U955 Inserm - UPEC), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
Oncology
Cancer Research
Longitudinal study
Lung Neoplasms
Pembrolizumab
B7-H1 Antigen
Antineoplastic Agents
Immunological
0302 clinical medicine
non–small cell lung cancer
Carcinoma
Non-Small-Cell Lung
PD‐L1 tumor proportion score
Longitudinal Studies
Original Research
Aged
80 and over
biology
Real world
Middle Aged
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Survival Rate
030220 oncology & carcinogenesis
Cohort
Female
pembrolizumab
Adult
medicine.medical_specialty
[SDV.CAN]Life Sciences [q-bio]/Cancer
Antibodies
Monoclonal
Humanized
lcsh:RC254-282
PD-L1 tumor proportion score
03 medical and health sciences
PD-L1
Internal medicine
medicine
Humans
first‐line monotherapy
Radiology
Nuclear Medicine and imaging
Lung cancer
Adverse effect
non-small cell lung cancer
Aged
Retrospective Studies
Performance status
business.industry
Clinical Cancer Research
medicine.disease
Clinical trial
030104 developmental biology
biology.protein
first-line monotherapy
business
Follow-Up Studies
Zdroj: Cancer Medicine
Cancer Medicine, 2020, 9 (7), pp.2309-2316. ⟨10.1002/cam4.2806⟩
Cancer Medicine, Vol 9, Iss 7, Pp 2309-2316 (2020)
ISSN: 2045-7634
Popis: Background The KEYNOTE‐024 trial demonstrated that pembrolizumab, a PD‐1 inhibitor, significantly improves progression‐free survival (PFS) and overall survival (OS) in selected patients with previously untreated advanced non–small cell lung cancer (NSCLC) with a PD‐L1 tumor proportion score (TPS) ≥50% and without EGFR/ALK aberrations. The main aim of this study was to report the efficacy and safety profile of pembrolizumab in real‐life conditions. Method This was a French retrospective multicenter longitudinal study of 108 consecutive patients with advanced NSCLC, a PD‐L1 TPS ≥50% and without EGFR/ALK aberrations who were treated by pembrolizumab, in first line. Patient data were obtained from medical files. Results The main characteristics of the cohort were: median age [range] 66.7 [37‐87] years, 64.8% male, 23.1% with a performance status (PS) of 2, and 88.9% current or former smokers. Eighty‐seven percent had stage IV NSCLC at diagnosis, 9.2% untreated brain metastases at inclusion,. With a median follow‐up of 8.2 months, the median PFS was 10.1 months (95% CI, 8.8‐11.4). The objective response rate was 57.3% (complete response 2.7%, partial response 54.6%). Disease control rate was 71.1%. At 6 months, the OS rate estimated was 86.2%. Treatment‐related adverse events (AE) of grade 3 occurred in 8% of patients. There were no grade 4 or 5 AEs. Conclusion In a real‐life cohort of advanced NSCLC patients (including PS 2 and untreated brain metastases), with PD‐L1 TPS ≥50%, pembrolizumab demonstrates similar PFS to the pivotal clinical trial.
This retrospective multicenter longitudinal study was intended to report the efficacy and safety profile of pembrolizumab in real‐life conditions for the first‐line treatment of advanced squamous none small‐cell lung cancer. The median progression free survival was 10.1 months (95% CI, 8.8‐11.4) and the treatment‐related adverse events of grade 3 occurred in 8% of patients. This study demonstrates similar progression‐free survival to KEYNOTE‐024.
Databáze: OpenAIRE
Externí odkaz: